Pharming Group (NASDAQ:PHAR – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.
Analyst Ratings
This is a summary of recent recommendations and price targets for Pharming Group and Roivant Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pharming Group | 2 | 0 | 3 | 0 | 2.20 |
| Roivant Sciences | 1 | 2 | 10 | 1 | 2.79 |
Pharming Group currently has a consensus price target of $38.67, suggesting a potential upside of 301.52%. Roivant Sciences has a consensus price target of $45.64, suggesting a potential upside of 34.07%. Given Pharming Group’s higher possible upside, equities analysts plainly believe Pharming Group is more favorable than Roivant Sciences.
Earnings and Valuation
This table compares Pharming Group and Roivant Sciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pharming Group | $366.48 million | 1.86 | $2.85 million | $0.12 | 80.25 |
| Roivant Sciences | $7.53 million | 3,264.45 | -$299.77 million | ($0.53) | -64.23 |
Pharming Group has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Pharming Group and Roivant Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pharming Group | 2.51% | 3.40% | 1.90% |
| Roivant Sciences | -3,534.96% | -22.94% | -21.53% |
Risk & Volatility
Pharming Group has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Insider & Institutional Ownership
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Pharming Group beats Roivant Sciences on 8 of the 15 factors compared between the two stocks.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
